Generic Temodar Launched by Mylan

Article

Mylan has launched a generic version of Merck's Temodar capsules, which may be used to treat patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy, then as maintenance treatment.

Mylan has launched a generic version of Merck’s Temodar capsules, which may be used to treat patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy, then as maintenance treatment.

Mylan’s temozolomide capsules will come in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg dosage forms. The manufacturer announced the approval of its abbreviated new drug application on July 11, 2016.

The capsules had US sales of $176.5 million in the 12 months ending May 31, 2016, according to IMS Health.

The most common adverse reactions associated with Temodar are fatigue, headache, nausea, and vomiting. Allergic reactions have also been reported in some patients.

Temodar is not recommended for pregnant women, as it may cause fetal harm. At the moment, it is not known if Temodar may impact nursing mothers. Additionally, the drug has not been researched for use in pediatric patients.

Related Videos
Image credit:  Gorodenkoff | stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.